Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs & Aging
Published in: Drugs & Aging 1/2022

01-01-2022 | Nausea | Therapy in Practice

Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes

Authors: Jørn Herrstedt, Sanne Lindberg, Peter Clausager Petersen

Published in: Drugs & Aging | Issue 1/2022

Login to get access

Abstract

Chemotherapy-induced nausea and vomiting (CINV) are still two of the most feared side effects of cancer therapy. Although major progress in the prophylaxis of CINV has been made during the past 40 years, nausea in particular remains a significant problem. Older patients have a lower risk of CINV than younger patients, but are at a higher risk of severe consequences of dehydration and electrolyte disturbances following emesis. Age-related organ deficiencies, comorbidities, polypharmacy, risk of drug–drug interactions, and lack of compliance all need to be addressed in the older patient with cancer at risk of CINV. Guidelines provide evidence-based recommendations for the prophylaxis of CINV, but none of these guidelines offer specific recommendations for older patients with cancer. This means that the recommendations may lead to overtreatment in some older patients. This review describes the development of antiemetic prophylaxis of CINV focusing on older patients, summarizes recommendations from antiemetic guidelines, describes deficiencies in our knowledge of older patients, summarizes necessary precautions, and suggests some future perspectives for antiemetic research in older patients.
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.PubMed
2.
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. 2020. https://​gco.​iarc.​fr/​today. Accessed 01 July 2021.
3.
Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TA, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol. 2019;20:1493–505.PubMedPubMedCentral
4.
Jørgensen TL, Hallas J, Land LH, Herrstedt J. Comorbidity and polypharmacy in elderly cancer patients: the significance on treatment outcome and tolerance. J Geriatr Oncol. 2010;1:87–102.
5.
Herrstedt J. The latest consensus on antiemetics. Curr Opin Oncol. 2018;30:233–9.PubMed
6.
Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients in high risk of chemotherapy-induced nausea and vomiting. Ann Oncol. 2018;28:1260–7.
7.
Jordan K, Chan A, Gralla RJ, Jahn F, Rapoport B, Warr D, et al. 2016 updated MASCC/ESMO consensus recommendations: emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer. 2017;25:271–5.PubMed
8.
Ajeet G, Klepin HD, Feng T, Tew WP, Mohile SG, Owusu C, et al. Predictors of chemotherapy dose reduction at first cycle in patients aged 65 years and older with solid tumors. J Geriatr Oncol. 2015;6:133–40.
9.
Mizuno M, Hiura M, Kikkawa F, Numa F, Yaegashi N, Narahara H, et al. A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynaecologic cancer by the CINV Study Group of Japan. Gynecol Oncol. 2016;140:559–64.PubMed
10.
Hesketh PJ, Aapro M, Street JC, Carides AD. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18:1171–7.PubMed
11.
Daiki T, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, et al. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer. 2019;27:1139–47.
12.
Rha SY, Park Y, Song SK, Lee CE, Lee J. Controlling chemotherapy-induced nausea requires further improvement: symptom experience and risk factors among Korean patients. Support Care Cancer. 2016;24:3379–89.PubMed
13.
Hayashi T, Shimokawa M, Matsuo K, Miyoshi T, Toriyama Y, Yokota C. Risk factors for delayed chemotherapy-induced nausea and vomiting with low-emetic-risk chemotherapy: a prospective, observational, multicenter study. Cancer Manag Res. 2018;10:4249–55.PubMedPubMedCentral
14.
Furukawa N, Akasaka J, Shigemitsu A, Sasaki Y, Nagai A, Kawaguchi R, et al. Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin. Arch Gynecol Obstet. 2014;289:859–64.PubMed
15.
Tsuji Y, Baba H, Takeda K, Kobayashi M, Oki E, Gotoh M, et al. Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opin Pharmacother. 2017;18:753–8.PubMed
16.
Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol. 2012;23:1986–92.PubMed
17.
ESMO Handbook of Cancer in the Senior Patient. In: Matti SA, Dirk S. editors. 2nd ed. 2015.
18.
Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology Consensus on geriatric asessment in older people with cancer. J Clin Oncol. 2014;32:2595–603.PubMedPubMedCentral
19.
Soenen S, Rayner CK, Jones KL, Horowitz M. The ageing gastrointestinal tract. Curr Opin Nutr Metab Care. 2016;19:12–8.
20.
Tveito M, Smith RL, Molden E, et al. Age impacts olanzapine exposure differently during use of oral versus long-acting injectable formulations: an observational study including 8,288 patients. J Clin Psychopharmacol. 2018;38:570–6.PubMed
21.
22.
Eriksen BO, Stefansson VTN, Jenssen TG, Mathisen UD, Schei J, Solbu MD, et al. Elevated blood pressure is not associated with accelerated glomerular filtration rate decline in the general non-diabetic middle-aged population. Kidney Int. 2016;90:404–10.PubMed
23.
Peterson LL, Hurria A, Feng T, et al. Association betweeen renal function and chemotherapy-related toxicity in older adults with cancer. J Geriatr Oncol. 2017;8:96–1010.PubMed
24.
Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. 2012;8:143–64.PubMedPubMedCentral
25.
Brygger L, Herrstedt J. 5-Hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf. 2014;13:1407–22.PubMed
26.
Hartsock RJ, Smith EB, Petty CS. Normal variants with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol. 1965;43:326–31.PubMed
27.
Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90:190–9.PubMed
28.
Guida JL, Agurs-Collins T, Ahles TA, Campisi J, Dale W, Demark-Wahnefried W, et al. Stategies to prevent or remediate cancer and treatment-related aging. J Natl Cancer Inst. 2021;113:112–22.PubMed
29.
Chudiak A, Uchmanowicz I, Mazur G. Relation between cognitive impairment and treatment adherence in elderly hypertensive patients. Clin Intervent Aging. 2018;13:1409–18.
30.
Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent patterns of multimorbidity among older adults in high-income countries. Popul Health Manag. 2019;22:127–37.PubMed
31.
Jørgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106:1353–60.PubMedPubMedCentral
32.
33.
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMed
34.
Linn BS, Lin MW, Gurel L. Cumulative illness rating scale. J Am Geriatr Soc. 1968;16:622–6.PubMed
35.
Masnoon N, Shakib S, Ellett LK, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17:230.PubMedPubMedCentral
36.
Corbett T, Bridges J. Multimorbidity in older adults living with and beyond cancer. Curr Opin Support Palliat Care. 2019;13:220–4.PubMed
37.
Korc-Grodzicki B, Boparai MK, Lichtman SM. Prescribing for older patients with cancer. Clin Adv Hematol Oncol. 2014;12:309–18.PubMed
38.
Jørgensen TL, Herrstedt J, Friis S, Hallas J. Polypharmacy and drug use in elderly Danish cancer patients during 1996–2006. J Geriatr Oncol. 2012;3:33–40.
39.
Beinse G, Reitter D, Segaux L, Carvahlo-Verlinde M, Rousseau B, Tournigand C, et al. Potential drug–drug interactions and risk of umplanned hospitalization in older patients with cancer: a survey of the prospective ELCAPA (ELderly CAncer PAtients) cohort. J Geriatr Oncol. 2020;11:586–92.PubMed
40.
Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophane as reserpine antagonists. Nature. 1957;180:1200.PubMed
41.
Shen WW, Baig MS, Sata LS, Hofstatter L. Dopamine receptor supersensitivity and the chemoreceptor trigger zone. Biol Psychiatry. 1983;18:917–21.PubMed
42.
Yoshida N, Yoshikawa T, Hosoki K. A dopamine D3 receptor agonist, 7-OH-DPAT, causes vomiting in the dog. Life Sci. 1995;57:347–50.
43.
Herrstedt J, Summers Y, Jordan K, Von Pawel J, Jakobsen AH, Ewertz M, Chan S, Naik JD, Karthaus M, Dubey S, Davis R, Fox GM. Amisulpride prevents nausea and vomiting associated with highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled, dose-ranging trial. Support Care Cancer. 2019;27:2699–705.PubMed
44.
Moertel C, Reitemeier RJ. Controlled clinical studies of orally administered antiemetic drugs. Gastroenterology. 1969;57:262–8.PubMed
45.
Moertel C, Reitemeier RJ. Controlled studies of metopimazine for the treatment of nausea and vomiting. J Clin Pharmacol. 1973;13:283–7.PubMed
46.
Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P. Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med. 1993;328:1076–80.PubMed
47.
Herrstedt J, Sigsgaard T, Handberg J, Schousboe BMB, Hansen M, Dombernowsky P. Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer. J Clin Oncol. 1997;15:1690–6.PubMed
48.
Jolliet P, Nion S, Allain-Veyrac G, Tilloy-Fenart L, Vanuxeem D, Berezowsky V, Cecchelli R. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res. 2007;56:11–7.PubMed
49.
Frytak S, Moertel CG, Eagan RT, O’Fallon JR. A double-blind comparison of metoclopramide and prochlorpearzine as antiemetics for platinum therapy. Proc Am Soc Clin Oncol. 1981;22:421.
50.
Olver IN, Wolf M, Laidlaw C, Bishop JF, Cooper IA, Matthews J, Smith R, Buchanan L. A randomised double-blind study of high-dose intravenous prochlorperazine versus high-dose metoclopramide as antiemetics for cancer chemotherapy. Eur J Cancer. 1992;28A:1798–802.PubMed
51.
Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302:135–8.PubMed
52.
Roscoe JA, Heckler CE, Morrow GR, Mohile SG, Dakhil SR, Wade JL, Kuebler JP. Prevention of delayed nausea: A University Rochester Cancer Center Community Clinical Oncology Program Study of patients receiving chemotherapy. J Clin Oncol. 2012;30:3389–95.PubMedPubMedCentral
53.
Justin-Besancon L, Laville C. Action antiémétique du métoclopramide vis-à-vis de l’apomorphine et de l’hydergine. CR Soc Biol (Paris). 1964;158:723.
54.
Pinder RM, Brogden RN, Sawyer R, Speight TM, Avery GS. Metoclopramide: a review of its pharmacological properties and clinical use. Drugs. 1976;12:81–131.PubMed
55.
Cunningham D, Evans C, Gazet JC, Ford H, People A, Dearling J, Chappell D, Coombes C. Comparison of antiemetic efficacy of domperidone, metoclopramide, and dexamethasone in patients receiving outpatient chemotherapy regimens. BMJ. 1987;295(6592):250.PubMedPubMedCentral
56.
Gralla RJ, Itri L, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J med. 1981;305:905–9.PubMed
57.
Warrington PS, Allan SG, Cornbleet MA, MacPherson JS, Smyth JF, Leonard RCF. Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin. BMJ. 1986;293:1334–7.PubMedPubMedCentral
58.
Kris MG, Gralla RJ, Clark RA, Tyson LB, Groshen S. Antiemetic control and prevention of side effects of antiemetic cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide and dexamethasone. Cancer. 1987;60:2816–22.PubMed
59.
Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, Malacarne P, Monici L, Di Costanzo F, Patoia L, Ballatori E, Tognoni G, Del Favero A. Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol. 1989;7:1693–700.PubMed
60.
Fozard JR, Mobarok ALIA. Blockade of neuronal tryptamine receptors by metoclopramide. Eur J Pharmacol. 1978;49:109–12.PubMed
61.
Fozard JR. MDL 72222, a potent and highly antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1984;326:36–44.PubMed
62.
Miner WD, Sanger GJ. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M receptor antagonism. Br J Pharmacol. 1986;88:497–9.PubMedPubMedCentral
63.
Costall B, Domeney AM, Naylor RJ, Tattersall FD. 5-hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacol. 1986;25:959–61.
64.
Joss RA, Goldhirsch A, Brunner KW, Galeazzi RL. Sudden death in cancer patients after high-dose domperidone. Lancer. 1982;1:1019.
65.
Roussak JB, Carey P, Parry H. Cardiac arrest after treatment with intravenous domperidone. BMJ. 1984;8:1579.
66.
Giaccone G, Bertetto O, Calciati A. Two sudden deaths during prophylactic antiemetic treatment with high doses of domperidone and methylprednisolone. Lancet. 1984;8:1336.
67.
Osborne RJ, Slevin ML, Hunter RW, Hamer J. Cardiotoxicity of intravenous domperidone. Lancet. 1985;17:385.
68.
Huys J. Cytostatic-associated vomiting effectively inhibited by domperidone (R 33812). Cancer Chenother Pharmacol. 1978;1:215–8.
69.
Roila F, Tonato M, Basurto C, Minotti V, Ballatori E, Del Favero A. Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. Eur J Cancer Clin Oncol. 1987;23:615–7.PubMed
70.
Baker JJ, Lokey JL, Price NA, Winokur SH, Bowen J. Nabilone as an antiemetic (use of high dose dexamethasone). N Engl J Med. 1979;301:728.PubMed
71.
Markman M, Sheidler V, Ettinger DS, Quaskey SA, Mellits ED. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med. 1984;311:549–52.PubMed
72.
Roila F, Tonato M, Cognetti F, Cortesi F, Favalli G, Marangolo M, Amadori D, Bella MA, Gramazio V, Donati D, Ballatori E, Del Favero A. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991;9:675–8.PubMed
73.
The Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med. 1995;332:1–5.
74.
Leibundgut U, Lancranjan I. First results with ICS 205–930 (5-HT3 receptor antagonis) in prevention of chemotherapy-induced emesis. Lancet. 1987;1(8543):1198.PubMed
75.
Cunningham D, Hawthorn J, Pople A, Gazet J-C, Ford HT, Challoner T, Coombes RC. Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet. 1987;1(8548):1461–3.PubMed
76.
Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med. 1990;322:810–6.PubMed
77.
Cubeddu LX, Hoffman IS, Fuenmayor NT, Finn AL. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. J Clin Oncol. 1990;8:1721–7.PubMed
78.
Marty M, Pouillart P, Scholl S, Droz JP, Azab M, Brion N, Pujade-Lauraine E, Paule B, Paes D, Bons J. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med. 1990;322:816–21.PubMed
79.
Bonneterre J, Chevallier B, Metz R, Fargeot P, Pujade-Lauraine E, Spielmann M, Tubiana-Hulin M, Paes D, Bons J. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. J Clin Oncol. 1990;8:1063–9.PubMed
80.
Kaasa S, Kvaløy S, Dicato MA, Ries F, Huys JV, Royer E, Carruthers L, International Emesis Study Group. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, double-blind study. International Emesis Study Group. Eur J Cancer. 1990;26:311–4.PubMed
81.
Marschner NW, Adler M, Nagel GA, Christmann D, Fenzl E, Upadhyaya B. Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer. 1991;27:1137–40.PubMed
82.
Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, Sikora K, Carney DN, Cunningham D. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet. 1991;24(338):483–7.
83.
Warr D, Willan A, Fine S, Wilson K, Davis A, Erlichman C, Rusthoven J, Lofters W, Osoba D, Laberge F, Latreille J, Pater J. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst. 1991;83:1169–73.PubMed
84.
Warr D, Wilan A, Venner P, Pater J, Kaizer L, Laberge F, Latreille J, Stewart D, O’Connell G, Osoba D, Wilson K, Davis A, Johnston D. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial. Eur J Cancer. 1992;29A:33–6.PubMed
85.
Perez EA, Hesketh P, Sandbach J, Reeves J, Chawla S, Markman M, Hainsworth J, Bushnell W, Friedman C. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol. 1998;16:754–60.PubMed
86.
Gralla RJ, Navari RM, Hesketh PJ, Popovic W, Strupp J, Noy J, Einhorn L, Ettinger D, Bushnell W, Friedman C. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998;16:1568–73.PubMed
87.
Raftopoulos H, Cooper W, O’Boyle E, Gabrail N, Boccia R, Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferiority, phase 3 trial. Support Care Cancer. 2015;23:723–32.PubMed
88.
Gralla R, Lichinitser M, Van der Vegt S, Sleeboom H, Mezger J, Peschel C, Tonini G, Labianca R, Macciocchi A, Aapro M. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570–7.PubMed
89.
Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer. 2003;98:2473–82.PubMed
90.
Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006;17:1441–9.PubMed
91.
Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–24.PubMed
92.
Morganroth J, Flaharty KK, Parisi S, Moresino C. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTC interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Support Care Cancer. 2016;24:621–7.PubMed
93.
Min JJ, Yoo Y, Kim TK, Lee J-M. Intravenous palonosetron increases the incidence of QTC prolongation during sevoflurane general anesthesia for laparotomy. Korean J Anesthesiol. 2013;65:397–402.PubMedPubMedCentral
94.
95.
Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay P-B, Possinger K, Roots I, Brockmöller J. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20:2805–11.PubMed
96.
Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. J Natl Cancer Inst. 1997;89:817–8.PubMed
97.
Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, Kindler H, Grote TH, Pendergrass K, Grunberg SM, Carides AD, Gertz B, for The L-754,030 Antiemetic Trials Group. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999;340:190–5.PubMed
98.
Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, Martinez-Cedillo J, Erazo A, Wittreich J, Eriksson L-O, Carides AD, Gertz BJ. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001;19:1759–67.PubMed
99.
Cocquyt V, Van Belle S, Reinhardt RR, Decramer MLA, O’Brien M, Schellens JHM, Borms M, Verbeke L, Van Aelst F, De Smet M, Carides AD, Eldridge K, Gertz BJ. Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001;37:835–42.PubMed
100.
Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer MLA, Riviere A, Thant M, Brestan E, Bui B, Eldridge K, De Smet M, Michiels N, Reinhardt RR, Carides AD, Evans JK, Gertz BJ. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002;94:3032–41.PubMed
101.
Chawla SP, Grunberg SM, Gralla RJ, Hesketh PJ, Rittenberg C, Elmer ME, Schmidt C, Taylor A, Carides AD, Evans JK, Horgan KJ. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:2290–300.PubMed
102.
Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, De Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–9.PubMed
103.
Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Ma GJ, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F, on behalf of the Aprepitant Protocol 054 Study Group. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090–8.PubMed
104.
Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim H-H, Park K, Jordan K, Von Pawel J, Giezek H, Ahmed T, Chan CY. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol. 2006;17:1000–6.PubMed
105.
Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F. Efficacy and toilerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–30.PubMed
106.
Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll H-J. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. 2010;18:423–31.PubMed
107.
Herrstedt J, Muss HB, Warr DG, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 2005;104:1548–55.PubMed
108.
Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol–EASE. J Clin Oncol. 2011;29:1495–501.PubMed
109.
Hesketh PJ, Rossi G, Rizzi G, et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol. 2014;25:1340–6.PubMedPubMedCentral
110.
Aapro M, Rugo H, Rossi G, et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol. 2014;25:1328–33.PubMedPubMedCentral
111.
Aapro M, Karthaus M, Schwartzberg L, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Hansen V, Rossi G, Rizzi G, Borroni ME, Rugo H. NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron. Support Care Cancer. 2017;25:1127–35.PubMed
112.
Gralla RJ, Bosnjak SM, Hontsa A, et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol. 2014;25:1333–9.PubMedPubMedCentral
113.
Schwartzberg L, Roeland E, Andric Z, Kowalski D, Radic J, Voisin D, Rizzi G, Navari R, Gralla RJ, Karthaus M. Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy. Ann Oncol. 2018;29:1535–40.PubMed
114.
Schwartzberg L, Navari R, Clark-Snow R, Arkania E, Radyukova I, Patel K, Voisin D, Rizzi G, Wickham R, Gralla RJ, Aapro M, Roland E. Phase IIIB safety and efficacy of intravenous NEPA for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer receiving initial and repeat cycles of anthracycline and cyclophosphamide (AC) chemotherapy. Oncologist. 2020;25:e589–97.PubMed
115.
Rapoport B, Chua D, Poma A, Arora S, Wang Y, Fein LE. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer. 2015;23:3281–8.PubMed
116.
Rapoport BL, Chasen MR, Gridelli C, Urban L, Modiano MR, Schnadig ID, Poma A, Arora S, Kansra V, Schwartzberg LS, Navari RM. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16:1079–89.PubMed
117.
Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16:1071–8.PubMed
118.
Navari RM. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Exp Opin Drug Saf. 2019;18:1127–32.
119.
Walton GD. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Adv Ther. 2019;36:662–9.PubMedPubMedCentral
120.
Meiri E, Jhangiani H, Vredenburgh JJ, Barbato LM, Carter FJ, Yang H-M, Baranowski V. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533–43.PubMed
121.
Grimison R, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber R, Olver I, Walsh A, McGregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J, Stockler M. Oral TCH: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomized, placebo-controlled, phase 2 crossover trial. Ann Oncol. 2020;31:1553–60.PubMed
122.
Chow R, Valdez C, Chow N, Zhang D, Im J, Sodhi E, Lock M. Oral cannabinoid for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis. Support Care Cancer. 2020;28:2095–103.PubMed
123.
Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58(suppl 10):28–36.PubMed
124.
Navari RM, Einhorn LH, Passik SD, Loehrer PJ Sr, Johnson C, Mayer ML, McClean J, Vinson J, Pletcher W. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer. 2005;13:529–34.PubMed
125.
Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, Chowhan N, Hanna NH, Johnson CS. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotheraåy-induced nausea and vomiting: a Hoosier Oncology Group Study. Support Care Cancer. 2007;15:1285–91.PubMed
126.
Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N. A randomized, double-blind phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol. 2018;23:382–8.PubMed
127.
Tanaka K, Inui N, Karayama M, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Kusagaya H, Matsuura S, Uto T, Hashimoto D, Matsui T, Asada K, Suda T. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting. Cancer Chemother Pharmacol. 2019;84:147–53.PubMed
128.
Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–95.PubMed
129.
Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375:134–42.PubMedPubMedCentral
130.
Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T, Hoshina Y, Sakata Y, Takashi TY, Nakashima K, Nakao M, Takei D, Zenda S, Mizukami K, Iwasa S, Sakurai M, Yamamoto N, Ohe Y. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicenter, randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2020;21:242–9.PubMed
131.
Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E, Lock M, DeAngelis C, Navari RM. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer. 2021;29:3439–59.PubMed
132.
Zhou J-G, Huang L, Jin S-H, Xu C, Frey B, Ma H, Gaipl US. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonisy (5-HT3RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogemic chemotherapy: a systematic review and meta-analysis of randomized controlled trials. ESMP Open. 2020;5: e000621. https://​doi.​org/​10.​1136/​esmoopen-2019-000621.CrossRef
133.
Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, Van der Wetering M, on behalf of the participants of MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016;27:v119–33.PubMed
134.
135.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis L, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Lyman GH. Antiemetics: ASCO guideline update. J Clin Oncol. 2020;38:2782–97.PubMed
136.
137.
Martin M, Diaz-Rubio E, Sanchez A, Almenarez J, López-Vega JM. The natural course of emesis after carboplatin treatment. Acta Oncol. 1990;29:593–5.PubMed
138.
Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, Mandel JJ, Lin SH, Smith BD, Smith GL, VanderWalde NA, Minsky BD, Koong AC, Stinchcombe TE, Jagsi R, Gomez DR, Thomas CR, Fuller CD. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5:1769–73.PubMed
139.
Lackman M, Vickers MM, Hsu T. Physician-reported reasons for non-enrollment of older adults in cancer clinical trials. J Geriatr Oncol. 2020;11:31–6.PubMed
140.
Malakoff D. Spiraling costs threaten gridlock. Science. 2008;322:210–3.PubMed
141.
Celio L, Bonizzoni E, Bajetta E, Sebastiani S, Perrone T, Aapro MS. Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two phase III trials. Support Care Cancer. 2013;21:565–73.PubMed
142.
Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M, Tsugawa K, Kojima Y, Furuya N, Matsuzaki K, Fukuda M, Sugae S, Ohta I, Arioka H, Tokuda Y, Narui K, Tsuboya A, Suda T, Morita S, Boku N, Yamanaka T, Nakajima TE. Placebo-controlled, double-blind phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 3 with combined neurokinin-1 receptor antagonist and palonosetron in high-emetogenic chemotherapy. J Clin Oncol. 2018;36:1000–6.PubMed
143.
Celio L, Cortinovis D, Cogoni AA, Cavanna L, Martelli O, Carnio S, Collova E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Pisconti S, Vittimberga I, Letizia A, Misino A, Gernone A, Bonizzoni E, Pilotto S, De Placido S, Bria E. Dexamethasone-sparing regimens with oral netupitant and palonosetron for the prevention of emesis caused by high-dose cisplatin: a randomized non-inferiority study. Oncologist. 2021. https://​doi.​org/​10.​1002/​onco.​13851.CrossRefPubMedPubMedCentral
144.
Hayashi T, Shimokawa M, Mizuki F, Matsuo K, Kawada K, Nakano T, Egawa T. Efficacy of one-day versus multiple-day dexamethasone for chemotherapy-induced nausea and vomiting in lung cancer patients receiving carboplatin-based chemotherapy: a propensity score-matched analysis. Support Care Cancer. 2021;29:5029–35.PubMed
145.
Janowitz T, Kleeman S, Vonderheide RH. Reconsidering dexamethasone for antiemesis when combining chemotherapy and immunotherapy. Oncologist. 2021;26:269–73.PubMedPubMedCentral
146.
Grant RC, Rotstein C, Liu G, Forbes L, Vu K, Lee R, Ng P, Krzyzanowska M, Warr D, Knox J. Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada. Support Care Cancer. 2020;28:5031–6.PubMedPubMedCentral
147.
Chapell R, Aapro MS. Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies. J Geriatr Oncol. 2013;4:73–83.
148.
Aapro M, Jordan K, Gralla RJ, Rizzi G, Rossi G, Palmas M, Alyasova AV, Lisyanskaya AS, Bosnjak S, Hesketh PJ. Safety and efficacy of NEPA, an oral fixed combination of netupitant and palonosetron in older patients. J Geriatr Oncol. 2017;8:56–63.PubMed
Metadata
Title
Prevention of Chemotherapy-Induced Nausea and Vomiting in the Older Patient: Optimizing Outcomes
Authors
Jørn Herrstedt
Sanne Lindberg
Peter Clausager Petersen
Publication date
01-01-2022
Publisher
Springer International Publishing
Published in
Drugs & Aging / Issue 1/2022
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-021-00909-8

Other articles of this Issue 1/2022

Drugs & Aging 1/2022 Go to the issue

Original Research Article

The Effect of Aspirin on the Primary Prevention of Major Adverse Cardiac and Cerebrovascular Events in Chinese Older Adults: A Registration Study

Original Research Article

Frequency and Acceptance of Clinical Decision Support System-Generated STOPP/START Signals for Hospitalised Older Patients with Polypharmacy and Multimorbidity

Review Article

Clinical Considerations for Insulin Therapy in Older Adults with Type 1 Diabetes

Review Article

Management of Hyperglycemia in Older Adults with Type 2 Diabetes

Original Research Article

Non-Steroidal Anti-Inflammatory Drugs and Risk of Acute Kidney Injury and Hyperkalemia in Older Adults: A Retrospective Cohort Study and External Validation of a Clinical Risk Model

Original Research Article

Highly Variable Paracetamol Pharmacokinetics After Multiple Oral Dosing in Frail Older People: A Population Pharmacokinetic Analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits